Results 171 to 180 of about 70,073 (274)

Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Gerke MB, Bedmutha A, Marra A, Liu Y, Brown JT, Nazha B, Berchuck JE, Parikh RB, Ahmed S, Ciuro JA, Hartman C, McClintock GR, Caulfield S, Kucuk O, Carthon BC, Schuster DM, Muzahir S, Bilen MA.   +17 more
europepmc   +1 more source

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

JAMA Oncology, 2016
H. Scher, David S. K. Lu, N. Schreiber, J. Louw, R. Graf, H. Vargas, A. Johnson, A. Jendrisak, R. Bambury, D. Danila, B. McLaughlin, Justin Wahl, Stephanie B Greene, G. Heller, D. Marrinucci, M. Fleisher, R. Dittamore   +16 more
semanticscholar   +1 more source

MBD3 increased expression by BRD4 and facilitated castration-resistant prostate cancer cell proliferation by inhibiting PTEN. [PDF]

Discov Oncol
Pan L, Shen J, Li Z, Xie G, Chen C, Chen X.   +5 more
europepmc   +1 more source

Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. [PDF]

Cancer Sci
Shiota M, Tatarano S, Kamba T, Kamoto T, Igawa T, Masumori N, Uemura H, Mitsunari K, Sumiyoshi T, Uemura H, Higashijima K, Tokunaga S, Eto M.   +12 more
europepmc   +1 more source

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

Nature, 2018
A. Calcinotto, C. Spataro, E. Zagato, Diletta Di Mitri, Veronica S. Gil, M. Crespo, Gaston de Bernardis, M. Losa, M. Mirenda, E. Pasquini, A. Rinaldi, S. Sumanasuriya, Maryou B. K. Lambros, A. Neeb, R. Lucianò, C. Bravi, Daniel Nava-Rodrigues, D. Dolling, T. Prayer-Galetti, Ana Ferreira, A. Briganti, A. Esposito, S. Barry, W. Yuan, A. Sharp, J. D. de Bono, A. Alimonti   +26 more
semanticscholar   +1 more source

Real-World Treatment Patterns Before and After Metastatic Castration-Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital-Based, Multicenter Database. [PDF]

Prostate Cancer
Shiota M, Xu L, Oguri T, Tanaka M.
europepmc   +1 more source

ADAMTS9-AS2 Disrupts Docetaxel-Resistance in Castration-Resistant Prostate Cancer via Stemness Suppression and Ferroptosis Induction. [PDF]

Adv Sci (Weinh)
Liu J, Gao Y, Guo Y, Zhang J, Zhang W, Gu Z, Chen H, Jin C, Luo P, Mao S, Hao Y, Shi S, Yao X.   +12 more
europepmc   +1 more source

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine, 2016
C. Kratochwil, F. Bruchertseifer, F. Giesel, Mirjam Weis, F. Verburg, F. Mottaghy, K. Kopka, C. Apostolidis, U. Haberkorn, A. Morgenstern   +9 more
semanticscholar   +1 more source

Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption. [PDF]

Mol Ther Oncol
Hu B, Wu P, Zheng L, Yang H, Fan Y, Yang J, Tang L, Kong S, Zhu C, Yang M, Zhang J, Liu Q, Huang Y.   +12 more
europepmc   +1 more source